Ibogaine’s potential role in supporting reward system recovery across diagnostic boundaries
Frontiers in Pharmacology December 4, 2025 Maya Nicolas
Ibogaine, a compound from the Tabernanthe iboga plant, may restore reward-system function across multiple disorders—including addiction, OCD, PTSD, and eating disorders—by upregulating GDNF, modulating glutamate and dopamine signaling, and reopening neuroplasticity. These conditions share disrupted dopaminergic and glutamatergic signaling in mesocorticolimbic circuitry, leading to maladaptive reinforcement and motivational dysregulation. Historical, preclinical, and observational evidence suggests ibogaine acts on underlying reward dysfunction rather than only symptoms. However, safety concerns include hERG channel inhibition, requiring strict medical protocols. This review proposes a unified mechanism but notes the framework requires empirical validation.